Navigation Links
AMDL CEO Featured in CEOCFO Magazine; Details Progress on DR-70 International Commercialization Strategy & Confidence in FY2009 Financial Forecast

TUSTIN, Calif., June 17 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its Chairman and CEO Mr. Douglas MacLellan has been featured in CEOCFO Magazine - a daily online investment news publication that delivers market news and analysis to investors through exclusive interviews with venture capital and publicly-traded companies listed on US and International stock exchanges.

In his interview Mr. MacLellan comments on AMDL's continued focus to become a leading pharmaceutical company with three distinct and growing divisions that include In Vitro Diagnostics (IVD), High End Skin Care Products, and China-based Pharmaceuticals; and target goals of achieving profitability across AMDL's US and China-based operations by year end.

Mr. MacLellan also provided updates on AMDL's worldwide commercialization strategy for the Company's DR-70 (FDP) IVD cancer test saying, "We are leveraging last year's US FDA approval for DR-70 with the launch of an international commercialization and have already realized sales revenues in this division. I believe in vitro diagnostics will be a substantial segment for the AMDL -- one that absolutely has the potential to generate equivalent or better returns as compared to our China-based pharmaceutical division."

Since 2006 AMDL has achieved more than 100% in year-over-year gross revenue growth and remains on track with its FY2009 business milestones and financial guidance projections. The Company is featured as the "#1 Small-Cap Stock Pick for 2009" by Flaherty Financial News ( ), a New York-based investment newsletter, and was named one of the Top 5 fastest growing publicly-traded companies in Orange County by international consulting group Deloitte.

The CEOCFO interview of Mr. MacLellan has been published and is available upon request by emailing AMDL's Investor Relations at or by visiting the CEOCFO website located at (User subscription is required.) For additional information on AMDL, its portfolio of products and 2009 business strategy visit the Company's website at .

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    (Tel:) 206.310.5323

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007
4. Allscripts Featured in Microsoft HealthVault Worldwide Launch
5. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
6. Marteks lifesDHA(TM) Featured in New Beech-Nut(R) DHA Plus Baby Food and Cereals
7. Jenny McCarthy Featured at National Autism Conference in Atlanta, November 9
8. Morris Animal Foundation Featured on NASCAR Racecar to Raise Awareness of Pet Cancer
9. Effective Treatment for Fibromyalgia Featured on Oprah Winfrey Show You Dont Have to Live With That Agony!
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Marteks lifesDHA(TM) Featured in Dalco Foods Wellness Line Meat Products
Post Your Comments:
(Date:11/28/2015)... ... , ... Pixel Film Studios is back again with ProPanel: Pulse . ... endless. Users have full control over angle of view, speed method, start point, end ... to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape masks, ...
(Date:11/27/2015)... ... , ... The rapid speed at which Americans are aging ... is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. ... part of this equation: 80 percent of medical care occurs in the home, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices ... show that delves into an array of issues that are presently affecting Americans. Dedicated ... open dialogue, this show is changing the subjects consumers focus on, one episode at ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health ... both STEMI and Sepsis conditions present in similar ways and require time-critical intervention to ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
Breaking Medicine Technology: